Effects of Glucose Concentration on Propofol Cardioprotection against Myocardial Ischemia Reperfusion Injury in Isolated Rat Hearts

Journal of Diabetes Research

Volumn 2015, Issue , 2015, Pages

  Yao, Xinhua ^a   Li, Yalan ^b   Tao, Mingzhe ^b   Wang, Shuang ^c   Zhang, Liangqing ^c   Lin, Jiefu ^b   Xia, Zhengyuan ^c,d   Liu, Hui Min ^e  

^a Guangzhou Hospital of Traditional Chinese Medicine   (China)

^b THE FIRST AFFILIATED HOSPITAL OF JINAN UNIVERSITY   (China)

^c GUANGDONG MEDICAL UNIVERSITY   (China)

^d UNIVERSITY OF HONG KONG   (Hong Kong)

^e RENMIN HOSPITAL OF WUHAN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

CD36 ANTIGEN; CREATINE KINASE MB; ENDOTHELIN 1; FATTY ACID; GLUCOSE; PROPOFOL; TRIMETAZIDINE; REACTIVE OXYGEN METABOLITE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CONTROLLED STUDY; CORONARY ARTERY BLOOD FLOW; DRUG SENSITIVITY; GLYCEMIC CONTROL; HEART FUNCTION; HEART INFARCTION; HEART INFARCTION SIZE; HEART MUSCLE INJURY; HEART MUSCLE ISCHEMIA; HEART PROTECTION; HEART SURGERY; IMMUNOBLOTTING; ISOLATED HEART; MALE; NONHUMAN; OXIDATION; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REPERFUSION; REPERFUSION INJURY; ANIMAL; CARDIAC MUSCLE; DOSE RESPONSE; DRUG EFFECTS; HEART; HEART CONTRACTION; METABOLISM; MYOCARDIAL REPERFUSION INJURY; SPRAGUE DAWLEY RAT;

ANIMALS; DOSE-RESPONSE RELATIONSHIP, DRUG; GLUCOSE; HEART; MALE; MYOCARDIAL CONTRACTION; MYOCARDIAL ISCHEMIA; MYOCARDIAL REPERFUSION INJURY; MYOCARDIUM; PROPOFOL; RATS; RATS, SPRAGUE-DAWLEY; REACTIVE OXYGEN SPECIES;

EID: 84944342884     PISSN: 23146745     EISSN: 23146753     Source Type: Journal    
DOI: 10.1155/2015/592028     Document Type: Article

References (50)

1. D. T. Mangano, E. L. Layug, A. Wallace, and I. Tateo, "Effect of atenolol on mortality and cardiovascular morbidity after noncardiac surgery,"The New England Journal of Medicine, vol. 335, no. 23, pp. 1713-1720, 1996
2. S. Cook and S. Windecker, "Surgical versus percutaneous revascularization of coronary artery disease in diabetic patients," Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 23, no. 3, pp. 317-334, 2009
3. M. Roffi and F. R. Eberli, "Diabetes and acute coronary syndromes," Best Practice and Research: Clinical Endocrinology and Metabolism, vol. 23, no. 3, pp. 305-316, 2009
4. D. Eapen, G. L. Kalra, N. Merchant, A. Arora, and B. V. Khan, "Metabolic syndrome and cardiovascular disease in South Asians," Vascular Health and Risk Management, vol. 5, pp. 731-743, 2009
5. A. Frank, M. Bonney, S. Bonney, L. Weitzel, M. Koeppen, and T. Eckle, "Myocardial ischemia reperfusion injury: from basic science to clinical bedside," Seminars in Cardiothoracic and Vascular Anesthesia, vol. 16, no. 3, pp. 123-132, 2012
6. W. Wang, H. Zhang, G. Xue et al., "Exercise training preserves ischemic preconditioning in aged rat hearts by restoring the myocardial polyamine pool," Oxidative Medicine and Cellular Longevity, vol. 2014,Article ID 457429, 14 pages, 2014
7. R. Rodrigo,M. Libuy, F. Felíu, and D. Hasson, "Oxidative stressrelated biomarkers in essential hypertension and ischemiareperfusion myocardial damage," Disease Markers, vol. 35, no. 6, pp. 773-790, 2013
8. G. Niccoli, A. Celestini, C. Calvieri et al., "Patients with microvascular obstruction after primary percutaneous coronary intervention show a gp91phox (NOX2) mediated persistent oxidative stress after reperfusion," European Heart Journal: Acute Cardiovascular Care, vol. 2, no. 4, pp. 379-388, 2013
9. W. C. Stanley, F. A. Recchia, andG. D. Lopaschuk, "Myocardial substrate metabolism in the normal and failing heart," Physiological Reviews, vol. 85, no. 3, pp. 1093-1129, 2005
10. Q. Liu, J. C. Docherty, J. C. T. Rendell, A. S. Clanachan, and G. D. Lopaschuk, "High levels of fatty acids delay the recovery of intracellular pH and cardiac efficiency in post-ischemic hearts by inhibiting glucose oxidation," Journal of theAmerican College of Cardiology, vol. 39, no. 4, pp. 718-725, 2002
11. J. S. Jaswal, W. Keung, W. Wang, J. R. Ussher, and G. D. Lopaschuk, "Targeting fatty acid and carbohydrate oxidation- A novel therapeutic intervention in the ischemic and failing heart," Biochimica et Biophysica Acta, vol. 1813, no. 7, pp. 1333-1350, 2011
12. L. C. Heather, K. M. Pates, H. J. Atherton et al., "Differential translocation of the fatty acid transporter, FAT/CD36, and the glucose transporter, GLUT4, coordinates changes in cardiac substrate metabolism during ischemia and reperfusion," Circulation: Heart Failure, vol. 6, no. 5, pp. 1058-1066, 2013
13. Y. Liu, S. Lei, X. Gao et al., "PKCbeta inhibition with ruboxistaurin reduces oxidative stress and attenuates left ventricular hypertrophy and dysfuntion in rats with streptozotocininduced diabetes," Clinical Science, vol. 122, no. 4, pp. 161-173, 2012
14. B. P. C. Kok and D. N. Brindley, "Myocardial fatty acid metabolism and lipotoxicity in the setting of insulin resistance," Heart Failure Clinics, vol. 8, no. 4, pp. 643-661, 2012
15. P. J. Randle, P. B. Garland, C. N. Hales, and E. A. Newsholme, "The glucose fatty-acid cycle. Its role in insulin sensitivity and themetabolic disturbances of diabetes mellitus,"TheLancet, vol. 1, pp. 785-789, 1963
16. H. L. Lazar, S. R. Chipkin, C. A. Fitzgerald, Y. Bao, H. Cabral, and C. S. Apstein, "Tight glycemic control in diabetic coronary artery bypass graft patients improves perioperative outcomes and decreases recurrent ischemic events," Circulation, vol. 109, no. 12, pp. 1497-1502, 2004
17. K. Malmberg, "Prospective randomised study of intensive insulin treatment on long term survival after acute myocardial infarction in patients with diabetes mellitus," British Medical Journal, vol. 314, no. 7093, pp. 1512-1515, 1997
18. K. Malmberg, A. Norhammar, H. Wedel, and L. Rydén, "Glycometabolic state at admission: important riskmarker ofmortality in conventionally treated patients with diabetes mellitus and acutemyocardial infarction: long-termresults fromthe diabetes and insulin-glucose infusion in acute myocardial infarction (DIGAMI) study," Circulation, vol. 99, no. 20, pp. 2626-2632, 1999
19. K. Malmberg, L. Rydén, S. Efendic et al., "Randomized trial of insulin-glucose infusion followed by subcutaneous insulin treatment in diabetic patients with acute myocardial infarction (DIGAMI study): effects on mortality at 1 year," Journal of the American College of Cardiology, vol. 26, no. 1, pp. 57-65, 1995
20. G. van den Berghe, P. Wouters, F. Weekers et al., "Intensive insulin therapy in critically ill patients," The New England Journal of Medicine, vol. 345, no. 19, pp. 1359-1367, 2001
21. R. Turner, "Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33)," The Lancet, vol. 352, no. 9131, pp. 837-853, 1998
22. P. Rujirojindakul, T. Liabsuetrakul, E. McNeil et al., "Safety and efficacy of intensive intraoperative glycaemic control in cardiopulmonary bypass surgery: a randomised trial," Acta Anaesthesiologica Scandinavica, vol. 58, no. 5, pp. 588-596, 2014
23. S. Vega-López, S. Devaraj, and I. Jialal, "Oxidative stress and antioxidant supplementation in the management of diabetic cardiovascular disease," Journal of InvestigativeMedicine, vol. 52, no. 1, pp. 24-32, 2004
24. I. Vasileiou, T. Xanthos, E. Koudouna et al., "Propofol: a review of its non-anaesthetic effects," European Journal of Pharmacology, vol. 605, no. 1-3, pp. 1-8, 2009
25. Z. Huang, X. Zhong, M. G. Irwin et al., "Synergy of isoflurane preconditioning and propofol postconditioning reduces myocardial reperfusion injury in patients," Clinical Science (Lond), vol. 121, no. 2, pp. 57-69, 2011
26. Z. Xia, D. V. Godin, T. K. H. Chang, and D. M. Ansley, "Dosedependent protection of cardiac function by propofol during ischemia and early reperfusion in rats: effects on 15-F2t-isoprostane formation," Canadian Journal of Physiology and Pharmacology, vol. 81, no. 1, pp. 14-21, 2003
27. F. Tamaki, T. Oguchi, S. Kashimoto, A. Nonaka, and T. Kumazawa, "Effects of propofol on ischemia and reperfusion in the isolated rat heart compared with thiamylal," Japanese Heart Journal, vol. 42, no. 2, pp. 193-206, 2001
28. H. Yamanaka and Y. Hayashi, "Myocardial preconditioning in anesthesia: from bench to bedside," Masui, vol. 58, pp. 279-287, 2009
29. Z. Xia, D. V. Godin, and D. M. Ansley, "Propofol enhances ischemic tolerance of middle-aged rat hearts: effects on 15-F2tisoprostane formation and tissue antioxidant capacity," Cardiovascular Research, vol. 59, no. 1, pp. 113-121, 2003
30. H. Li, Z. Liu, J. Wang et al., "Susceptibility to myocardial ischemia reperfusion injury at early stage of type 1 diabetes in rats," Cardiovascular Diabetology, vol. 12, no. 1, article 133, 2013
31. Z. Xia, K.-H. Kuo, D. V. Godin, M. J. Walker, M. C. Y. Tao, and D. M. Ansley, "15-F2-isoprostane exacerbates myocardial ischemia-reperfusion injury of isolated rat hearts," The American Journal of Physiology-Heart and Circulatory Physiology, vol. 289, no. 4, pp. H1366-H1372, 2005
32. Z. Guo, Z. Xia, J. Jiang, and J. H. McNeill, "Downregulation of NADPH oxidase, antioxidant enzymes, and inflammatory markers in the heart of streptozotocin-induced diabetic rats by N-acetyl-L-cysteine," The American Journal of Physiology- Heart and Circulatory Physiology, vol. 292, no. 4, pp. H1728-H1736, 2007
33. J. D. Morrow, T. A. Minton, C. R. Mukundan et al., "Free radicalinduced generation of isoprostanes in vivo: evidence for the formation of D-ring and E-ring isoprostanes," The Journal of Biological Chemistry, vol. 269, no. 6, pp. 4317-4326, 1994
34. J. Nourooz-Zadeh, "Gas chromatography-mass spectrometry assay for measurement of plasma isoprostanes," Methods in Enzymology, vol. 300, pp. 13-17, 1999
35. F. G. Spinale, J. D. Walker, R. Mukherjee, J. P. Iannini, A. T. Keever, and K. P. Gallagher, "Concomitant endothelin receptor subtype-A blockade during the progression of pacing-induced congestive heart failure in rabbits: beneficial effects on left ventricular andmyocyte function," Circulation, vol. 95,no. 7, pp. 1918-1929, 1997
36. Z. Xia, J. Gu, D. M. Ansley, F. Xia, and J. Yu, "Antioxidant therapy with Salvia miltiorrhiza decreases plasma endothelin-1 and thromboxane B2 after cardiopulmonary bypass in patients with congenital heart disease," Journal of Thoracic and Cardiovascular Surgery, vol. 126, no. 5, pp. 1404-1410, 2003
37. D. M. Ansley, Z. Xia, and B. S. Dhaliwal, "The relationship between plasma free 15-F2t-isoprostane concentration and early postoperative cardiac depression following warm heart surgery," Journal of Thoracic and Cardiovascular Surgery, vol. 126, no. 4, pp. 1222-1223, 2003
38. H.-M. Liu, K.-X. Liu, M.-H. Cheng et al., "Bosentan affects 15-F2-isoprostane adverse effects on postischemic rat hearts," Journal of Surgical Research, vol. 168, no. 1, pp. 18-26, 2011
39. M. Kuang, M. Febbraio, C. Wagg, G. D. Lopaschuk, and J. R. B. Dyck, "Fatty acid translocase/CD36 deficiency does not energetically or functionally compromise hearts before or after ischemia," Circulation, vol. 109, no. 12, pp. 1550-1557, 2004
40. J. R. Ussher andG. D. Lopaschuk, "TargetingmalonylCoAinhibition ofmitochondrial fatty acid uptake as an approach to treat cardiac ischemia/reperfusion," Basic Research inCardiology, vol. 104, no. 2, pp. 203-210, 2009
41. L. Wang, K. W. S. Ko, E. Lucchinetti et al., "Metabolic profiling of hearts exposed to sevoflurane and propofol reveals distinct regulation of fatty acid and glucose oxidation: CD36 and pyruvate dehydrogenase as key regulators in anesthetic-induced fuel shift," Anesthesiology, vol. 113, no. 3, pp. 541-551, 2010
42. P. G. Murphy, D. S. Myers, M. J. Davies,N. R. Webster, and J. G. Jones, "The antioxidant potential of propofol (2,6-diisopropylphenol)," British Journal of Anaesthesia, vol. 68, no. 6, pp. 613-618, 1992
43. S. G. deHert, P. W. ten Broecke, E. Mertens et al., "Sevoflurane but not propofol preserves myocardial function in coronary surgery patients," Anesthesiology, vol. 97, no. 1, pp. 42-49, 2002
44. P. C. A. Kam and D. Cardone, "Propofol infusion syndrome," Anaesthesia, vol. 62, no. 7, pp. 690-701, 2007
45. N. Kokita, A. Hara, Y. Abiko, J. Arakawa, H. Hashizume, and A. Namiki, "Propofol improves functional andmetabolic recovery in ischemic reperfused isolated rat hearts," Anesthesia & Analgesia, vol. 86, no. 2, pp. 252-258, 1998
46. M. Jovic, A. Stancic, D. Nenadic et al., "Mitochondrial molecular basis of sevoflurane and propofol cardioprotection in patients undergoing aortic valve replacement with cardiopulmonary bypass," Cellular Physiology and Biochemistry, vol. 29, no. 1-2, pp. 131-142, 2012
47. C. Pantos, A. Bescond-Jacquet, S. Tzeis et al., "Trimetazidine protects isolated rat hearts against ischemia-reperfusion injury in an experimental timing-dependent manner," Basic Research in Cardiology, vol. 100, no. 2, pp. 154-160, 2005
48. M. Ikizler, N. Erkasap, S. Dernek, B. Batmaz, T. Kural, and Z. Kaygisiz, "Trimetazidine-induced enhancement of myocardial recovery during reperfusion: a comparative study in diabetic and non-diabetic rat hearts," Archives of Medical Research, vol. 37, no. 6, pp. 700-708, 2006
49. G. D. Lopaschuk,R. Barr, P. D. Thomas, and J. R. B. Dyck, "Beneficial effects of trimetazidine in ex vivo working ischemic hearts are due to a stimulation of glucose oxidation secondary to inhibition of long-chain 3-ketoacyl coenzyme a thiolase," Circulation Research, vol. 93, no. 3, pp. e33-e37, 2003
50. G. Fragasso, A. Salerno, G. Lattuada et al., "Effect of partial inhibition of fatty acid oxidation by trimetazidine on whole body energy metabolism in patients with chronic heart failure," Heart, vol. 97, no. 18, pp. 1495-1500, 2011.